These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9606478)

  • 1. Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals.
    Faris MA; Raasch RH; Hopfer RL; Butts JD
    Ann Pharmacother; 1998 May; 32(5):564-73. PubMed ID: 9606478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment].
    Schneider MM; Reiss P; Borleffs JC; Rozenberg-Arska M; Hoepelman IM
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):80-3. PubMed ID: 9036351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies for the prevention and treatment of disseminated Mycobacterium avium complex infection in patients with AIDS.
    Wright J
    Pharmacotherapy; 1998; 18(4):738-47. PubMed ID: 9692648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
    Cohn DL
    Drugs; 1997; 54 Suppl 2():8-15; discussion 28-9. PubMed ID: 9358195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in the management of Mycobacterium avium complex infection in AIDS patients.
    Peloquin CA
    Ann Pharmacother; 1993; 27(7-8):928-37. PubMed ID: 8364280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease.
    Dautzenberg B
    Drugs; 1997; 54 Suppl 2():1-7; discussion 28-9. PubMed ID: 9358194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.
    Pierce M; Crampton S; Henry D; Heifets L; LaMarca A; Montecalvo M; Wormser GP; Jablonowski H; Jemsek J; Cynamon M; Yangco BG; Notario G; Craft JC
    N Engl J Med; 1996 Aug; 335(6):384-91. PubMed ID: 8663871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease.
    Sterling TR; Moore RD; Graham NM; Astemborski J; Vlahov D; Chaisson RE
    AIDS; 1998 Aug; 12(12):1451-7. PubMed ID: 9727565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease.
    Hewitt RG; Papandonatos GD; Shelton MJ; Hsiao CB; Harmon BJ; Kaczmarek SR; Amsterdam D
    AIDS; 1999 Jul; 13(11):1367-72. PubMed ID: 10449290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options for the management and prevention of Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome.
    Tartaglione TA
    Pharmacotherapy; 1996; 16(2):171-82. PubMed ID: 8820462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection.
    Sesin GP; Manzi SF; Pacheco R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2585-90. PubMed ID: 8913387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS.
    Gordin F; Masur H
    Clin Infect Dis; 1994 Apr; 18 Suppl 3():S223-6. PubMed ID: 8204774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections.
    Amsden GW; Peloquin CA; Berning SE
    Drugs; 1997 Jul; 54(1):69-80. PubMed ID: 9211081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
    Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
    AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.
    Nightingale SD; Cameron DW; Gordin FM; Sullam PM; Cohn DL; Chaisson RE; Eron LJ; Sparti PD; Bihari B; Kaufman DL
    N Engl J Med; 1993 Sep; 329(12):828-33. PubMed ID: 8179648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus.
    Ostroff SM; Spiegel RA; Feinberg J; Benson CA; Horsburgh CR
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S72-6. PubMed ID: 8547516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex.
    Masur H
    N Engl J Med; 1993 Sep; 329(12):898-904. PubMed ID: 8395019
    [No Abstract]   [Full Text] [Related]  

  • 18. Disseminated Mycobacterium avium complex disease in patients with AIDS.
    Benson C
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):913-6. PubMed ID: 7811542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
    N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
    Bayoumi AM; Redelmeier DA
    AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.